Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HB0036 |
Synonyms | |
Therapy Description |
HB0036 is a bispecific antibody that targets TIGIT and PD-L1 (CD274), which potentially induces antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr e14504). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HB0036 | HB-0036|HB 0036 | PD-L1/PD-1 antibody 121 TIGIT Antibody 19 | HB0036 is a bispecific antibody that targets TIGIT and PD-L1 (CD274), which potentially induces antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr e14504). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05417321 | Phase Ib/II | HB0036 | A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors | Recruiting | USA | 1 |